IP Library Granted Patent US 8,216,289
Granted Patent B2
US 8,216,289 · App. 12/969,999 · Granted Jul 10, 2012

Illuminator for photodynamic therapy

Assignee: Dusa Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,216,289
App. No.
12/969,999
Granted
Jul 10, 2012
Kind
B2
Abstract

An apparatus and method for photodynamic therapy or photodynamic diagnosis using an illuminator comprising a plurality of light sources generally conforming to a contoured surface and irradiating the contoured surface with substantially uniform intensity visible light. The light sources may comprise generally U-shaped fluorescent tubes that are driven by electronic ballasts. Adjustment of the ballast voltage controls the output power of the tubes. The tubes are supported by a sheet-metal or plastic housing and are covered by a polycarbonate shield which directs cooling airflow within the unit and prevents glass-patient contact in the vent of tube breakage. An aluminum reflector located behind the tubes increases both the output irradiance and the uniformity of the output distribution. The spacing of the U-shaped tubes is varied to increase the output at the edges of the illuminator to make the output more uniform. Also, different portions of the tubes are cooled at different amounts, to improve uniformity. A light sensor monitors output from the U-shaped tubes to provide a signal for adjusting the output from the tubes.

Claims (20)

1. A method of photodynamically diagnosing or treating a patient, comprising:

illuminating the patient with an illuminator whose measured output over an active emitting area is at least 60% of the measured maximum over all operation distances.

2. The method according to claim 1 , wherein the illuminator is configured such that the measured output over the active emitting area is at least 70% of the measured maximum at distances of 4″ and 2″.

3. The method according to claim 1 , wherein the illuminator comprises fluorescent tubes.

4. The method according to claim 1 , wherein the spectral output of the illuminator substantially matches the absorption spectrum of protoporphyrin IX.

5. The method according to claim 1 , wherein the illuminator generates light substantially entirely within the blue region.

6. The method according to claim 1 , wherein the illuminator has a nominal peak wavelength of 417±5 nanometers and a nominal bandwidth of 30 nanometers.

7. The method according to claim 1 , comprising illuminating the patient to treat actinic keratosis.

8. The method according to claim 1 , comprising illuminating the patient to treat acne.

9. The method according to claim 1 , comprising illuminating the patient to treat photo damaged skin.

10. The method according to claim 1 , comprising illuminating the patient to treat cancer.

11. The method according to claim 1 , comprising illuminating the patient to treat warts.

12. The method according to claim 1 , comprising illuminating the patient to treat psoriasis.

13. The method according to claim 1 , comprising illuminating the patient to remove hair.

14. The method according to claim 1 , comprising illuminating the patient to diagnose cancer.

15. The method according to claim 1 , comprising illuminating the patient to treat a pre-cancerous condition.

16. The method according to claim 1 , wherein the illuminator is configured such that the measured output over the active emitting area is at least 70% of the measured maximum at distances between 4″ and 2″.

17. The method according to claim 1 , wherein the illuminator is configured such that the measured output over the active emitting area is at least 70% of the measured maximum at a distance of 4″.

18. The method according to claim 1 , wherein the illuminator is configured such that the measured output over the active emitting area is at least 70% of the measured maximum at a distance of 2″.

19. The method according to claim 1 , wherein the illuminator is configured such that the measured output over the active emitting area is at least 70% of the measured maximum at a distance between 4″ and 2″.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2012
From: LUNDAHL, SCOTT; KOZODOY, REBECCA; CARROLL, RONALD; LEPPELMEIER, ELTON
To: DUSA PHARMACEUTICALS INC.
Reel/Frame 029034/0214 →
Continuity (6)
Continuation 12621845 · Nov 19, 2009
Continuation 11716014 · Mar 9, 2007
Continuation 10755318 · Jan 13, 2004
Division 09774084 · Jan 31, 2001
Division 09070772 · May 1, 1998
Related Publication 20110282266A1 · Nov 17, 2011